Therapeutic options for acute myelogenous leukemia

Cancer

Volumn 92, Issue 5, 2001, Pages 1059-1073

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia (AML); Cytogenetics; New agents; Transplantation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ACLARUBICIN; ANTHRACYCLINE DERIVATIVE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CD33 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ECHINOCANDIN B DERIVATIVE; EXATECAN; FLUDARABINE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; HUM 195; IDARUBICIN; METHYLPREDNISOLONE; MICAFUNGIN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD33; MONOCLONAL ANTIBODY M 195; POSACONAZOLE; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRROLE DERIVATIVE; TIPIFARNIB; TOPOTECAN; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VASCULOTROPIN INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOTRANSPLANTATION; BLOOD CELL COUNT; CLINICAL TRIAL; CYTOGENETICS; DATA BASE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; COLONY-STIMULATING FACTORS; CYTARABINE; CYTOGENETICS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROGNOSIS; TOPOTECAN; VIDARABINE;

EID: 0035446823     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010901)92:5<1059::AID-CNCR1421>3.0.CO;2-K     Document Type: Article

References (78)

1. The effect of chemotherapy on acute leukemia in the human
2. Treatment of relapsed and refractory acute myelogenous leukemia
3. Implications of potential cure in acute myelogenous leukemia: Development of subsequent cancer and return to work
4. Prognostic factors in acute myelogenous leukemia
5. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
6. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
7. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
8. The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy; analysis of 854 patients from the MRC AML 10 and 12
9. MLL-duplications are rare and associated with poor prognosis in acute myeloid leukemia
10. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study
11. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
12. Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features
13. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly-diagnosed acute myelogenous leukemia
14. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
15. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study
16. On the behalf of the AML Collaborative Group L: Meta-analysis of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML)
17. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study
18. Intensive postremission chemotherapy in adults with acute myeloid leukemia
19. Varying intensity of postremission therapy in acute myeloid leukemia
20. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: A review and updated results of the Australian Leukemia Study Group
21. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
22. How I treat older patients with AML
23. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group
24. Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients
25. Smoldering acute granulocytic leukemia. Observations on its natural history and morphologic characteristics
26. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia
27. Autologous or allgeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
28. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
29. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial
30. Biological characteristics of disease determine the outcome of allogeneic or autologous BMT in AML CR1
31. Transplantation in first remission of acute myeloid leukemia
32. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the Children's Cancer Group
33. Treatment of myeloid leukemias with non-myeloablative stem cell transplantation: Accomplishments and future goals
34. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission
35. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
36. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
37. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia
38. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia
39. Economic analysis of granulocyte colony stimulating factor (G-CSF) as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group (SWOG) Clinical Trial
40. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022
41. A phase II trial of subcutaneous recombinant human interleukin 11 (rhIL-11) with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: Eastern Cooperative Oncology Group 3997
42. Routine use of fludarabine-or topotecan-containing chemotherapy is not indicated in AML, RAEB-t or RAEB
43. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes
44. Efficacy and safety of recombinant human activated protein C for severe sepsis
45. Efficacy and safety of gemtuzumab ozogamicin in patients with cd33-positive acute myeloid leukemia in first relapse
46. Comparative efficacy and safety of gemtuzumab oxogamicin monotherapy and high-dose cytarabine combination therapy in the treatment of patients with acute myeloid leukemia in first relapse
47. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HUM195 in acute promyelocytic leukemia
48. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
49. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33)
50. Benefit of cycloporine (CsA) Modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group study
51. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (PTS) ≥ years (CALGB 9720)
52. Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (PTS) with acute myeloid leukemia (AML) < 60 years old: Preliminary results of CALGB 9621
53. RAS and leukemia: From basic mechanisms to gene-directed therapy
54. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary results of a phase I trial
55. Phase I trial of genasense™ (G3139, Genta, Inc.), a BCL-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL)
56. DNA methylation
57. Decitabine studies in chronic and acute myelogenous leukemia
58. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
59. Evidence of increased antiogenesis in patients with acute myeloid leukemia
60. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
61. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
62. Addition of thalidomide (T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS
63. Inhibition of the transforming activity of FLT3 internal tandem duplications derived from AML patients by a tyrosine kinase inhibitor of the tyrphostin class
64. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group
65. The impact of treatment on the outcome of cytogenetic subgroups in acute myeloid leukemia - Results of the German AML Cooperative Group
66. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
67. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
68. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience
69. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
70. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
71. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study
72. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial
73. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): The combine results and follow-up from the U.S. pilot and multicenter trials
74. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials
75. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
76. Selecting therapeutic strategies based on efficacy and death in multi-course clinical trials
77. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation